Pharmakotherapie der ventrikulären rhythmusstörungen. Was kommt, was bleibt, was geht?

F. T. Wegener, G. C. Grönefeld, G. Duray, J. R. Ehrlich, S. H. Hohnloser

Research output: Article

Abstract

This review summarizes the current status of pharmacological therapy for ventricular arrhythmias in symptomatic patients. The selection of specific drugs for this indication is highly dependent on the underlying heart disease. In primary prevention of sudden death, antiarrhythmic agents do not play a role - except betareceptor antagonists. Similarly, in patients treated for secondary prevention of cardiac arrest or hemodynamically symptomatic ventricular tachycardia, the implantable defibrillator constitutes the therapy of choice with hardly any role left for antiarrhythmic drugs. An emerging role for antiarrhythmic drug therapy is represented by the concomitant pharmacological treatment in ICD recipients who experience shocks from their devices (hybrid therapy). Several randomized clinical trials have recently evaluated this issue and permit an evidence-based treatment strategy. Currently, most patients receive sotalol or amiodarone for hybrid therapy with azimilide as a potential new class III antiarrhythmic drug for this treatment indication.

Original languageGerman
Pages (from-to)297-307
Number of pages11
JournalInternist
Volume47
Issue number3
DOIs
Publication statusPublished - márc. 2006

Fingerprint

Cardiac Arrhythmias
Pharmacology
Anti-Arrhythmia Agents
Therapeutics
Sotalol
Amiodarone
Implantable Defibrillators
Primary Prevention
Ventricular Tachycardia
Sudden Death
Secondary Prevention
Heart Arrest
Heart Diseases
Shock
Randomized Controlled Trials
Drug Therapy
Equipment and Supplies
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Pharmakotherapie der ventrikulären rhythmusstörungen. Was kommt, was bleibt, was geht? / Wegener, F. T.; Grönefeld, G. C.; Duray, G.; Ehrlich, J. R.; Hohnloser, S. H.

In: Internist, Vol. 47, No. 3, 03.2006, p. 297-307.

Research output: Article

Wegener, F. T. ; Grönefeld, G. C. ; Duray, G. ; Ehrlich, J. R. ; Hohnloser, S. H. / Pharmakotherapie der ventrikulären rhythmusstörungen. Was kommt, was bleibt, was geht?. In: Internist. 2006 ; Vol. 47, No. 3. pp. 297-307.
@article{345383502b83405c97d6568ed28669ea,
title = "Pharmakotherapie der ventrikul{\"a}ren rhythmusst{\"o}rungen. Was kommt, was bleibt, was geht?",
abstract = "This review summarizes the current status of pharmacological therapy for ventricular arrhythmias in symptomatic patients. The selection of specific drugs for this indication is highly dependent on the underlying heart disease. In primary prevention of sudden death, antiarrhythmic agents do not play a role - except betareceptor antagonists. Similarly, in patients treated for secondary prevention of cardiac arrest or hemodynamically symptomatic ventricular tachycardia, the implantable defibrillator constitutes the therapy of choice with hardly any role left for antiarrhythmic drugs. An emerging role for antiarrhythmic drug therapy is represented by the concomitant pharmacological treatment in ICD recipients who experience shocks from their devices (hybrid therapy). Several randomized clinical trials have recently evaluated this issue and permit an evidence-based treatment strategy. Currently, most patients receive sotalol or amiodarone for hybrid therapy with azimilide as a potential new class III antiarrhythmic drug for this treatment indication.",
keywords = "Antiarrhythmics, Hybrid therapy, Implantable cardioverter defibrillator, Sudden cardiac death, Ventricular arrhythmia",
author = "Wegener, {F. T.} and Gr{\"o}nefeld, {G. C.} and G. Duray and Ehrlich, {J. R.} and Hohnloser, {S. H.}",
year = "2006",
month = "3",
doi = "10.1007/s00108-005-1561-z",
language = "German",
volume = "47",
pages = "297--307",
journal = "Der Internist",
issn = "0020-9554",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Pharmakotherapie der ventrikulären rhythmusstörungen. Was kommt, was bleibt, was geht?

AU - Wegener, F. T.

AU - Grönefeld, G. C.

AU - Duray, G.

AU - Ehrlich, J. R.

AU - Hohnloser, S. H.

PY - 2006/3

Y1 - 2006/3

N2 - This review summarizes the current status of pharmacological therapy for ventricular arrhythmias in symptomatic patients. The selection of specific drugs for this indication is highly dependent on the underlying heart disease. In primary prevention of sudden death, antiarrhythmic agents do not play a role - except betareceptor antagonists. Similarly, in patients treated for secondary prevention of cardiac arrest or hemodynamically symptomatic ventricular tachycardia, the implantable defibrillator constitutes the therapy of choice with hardly any role left for antiarrhythmic drugs. An emerging role for antiarrhythmic drug therapy is represented by the concomitant pharmacological treatment in ICD recipients who experience shocks from their devices (hybrid therapy). Several randomized clinical trials have recently evaluated this issue and permit an evidence-based treatment strategy. Currently, most patients receive sotalol or amiodarone for hybrid therapy with azimilide as a potential new class III antiarrhythmic drug for this treatment indication.

AB - This review summarizes the current status of pharmacological therapy for ventricular arrhythmias in symptomatic patients. The selection of specific drugs for this indication is highly dependent on the underlying heart disease. In primary prevention of sudden death, antiarrhythmic agents do not play a role - except betareceptor antagonists. Similarly, in patients treated for secondary prevention of cardiac arrest or hemodynamically symptomatic ventricular tachycardia, the implantable defibrillator constitutes the therapy of choice with hardly any role left for antiarrhythmic drugs. An emerging role for antiarrhythmic drug therapy is represented by the concomitant pharmacological treatment in ICD recipients who experience shocks from their devices (hybrid therapy). Several randomized clinical trials have recently evaluated this issue and permit an evidence-based treatment strategy. Currently, most patients receive sotalol or amiodarone for hybrid therapy with azimilide as a potential new class III antiarrhythmic drug for this treatment indication.

KW - Antiarrhythmics

KW - Hybrid therapy

KW - Implantable cardioverter defibrillator

KW - Sudden cardiac death

KW - Ventricular arrhythmia

UR - http://www.scopus.com/inward/record.url?scp=33645284437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645284437&partnerID=8YFLogxK

U2 - 10.1007/s00108-005-1561-z

DO - 10.1007/s00108-005-1561-z

M3 - Article

C2 - 16418866

AN - SCOPUS:33645284437

VL - 47

SP - 297

EP - 307

JO - Der Internist

JF - Der Internist

SN - 0020-9554

IS - 3

ER -